Suvretta Capital Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Suvretta Capital Management’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,914,000	Closed	-$1.66M	–	111
2022 Q3	$1.66M	Hold	5,914,000	–	–	0.07%	66
2022 Q2	$2.13M	Hold	5,914,000	–	–	0.08%	77
2022 Q1	$3.96M	Hold	5,914,000	–	–	0.12%	66
2021 Q4	$7.63M	Buy	5,914,000 +425,000	+8%	+$754K	0.15%	66
2021 Q3	$11.9M	Hold	5,489,000	–	–	0.2%	60
2021 Q2	$15M	Hold	5,489,000	–	–	0.22%	67
2021 Q1	$14.3M	Buy	+5,489,000	New	+$15.5M	0.21%	66

Other funds holding SIOX

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

TVWM

Tower View Wealth Management Shorewood, Wisconsin $227M AUM 41.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Suvretta Capital Management's SIOX Position: Q4 2022 in Review

Suvretta Capital Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2022, closing a stake of 5,914,000 shares — an estimated $1.66M sold.

Suvretta Capital Management first reported a position in SIOX in Q1 2021 and held it in 7 quarters. The position peaked at $15M in Q2 2021. 37 funds tracked by Wall St. Rank hold SIOX as of Q4 2022.

Suvretta Capital Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Suvretta Capital Management sold 5,914,000 Sio Gene Therapies Inc. Common Stock shares in Q4 2022, an estimated $1.66M.
Suvretta Capital Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Suvretta Capital Management's Sio Gene Therapies Inc. Common Stock position peaked at $15M in Q2 2021.
37 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2022.

Based on Suvretta Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.